000176959 001__ 176959
000176959 005__ 20240229133726.0
000176959 0247_ $$2doi$$a10.1016/j.ejca.2021.08.019
000176959 0247_ $$2pmid$$apmid:34521064
000176959 0247_ $$2ISSN$$a0014-2964
000176959 0247_ $$2ISSN$$a0959-8049
000176959 0247_ $$2ISSN$$a1879-0852
000176959 0247_ $$2ISSN$$a(1990)
000176959 0247_ $$2ISSN$$a1879-2995
000176959 0247_ $$2ISSN$$a(1965)
000176959 037__ $$aDKFZ-2021-02192
000176959 041__ $$aEnglish
000176959 082__ $$a610
000176959 1001_ $$0P:(DE-He78)d62d536fb73eb7644201ddaac56cf68f$$aPouyiourou, Maria$$b0$$eFirst author$$udkfz
000176959 245__ $$aLocal ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary.
000176959 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2021
000176959 3367_ $$2DRIVER$$aarticle
000176959 3367_ $$2DataCite$$aOutput Types/Journal article
000176959 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634106192_10608
000176959 3367_ $$2BibTeX$$aARTICLE
000176959 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000176959 3367_ $$00$$2EndNote$$aJournal Article
000176959 500__ $$a#EA:A360#LA:A360#
000176959 520__ $$aSingle-site carcinoma of unknown primary (CUP) is recognised as a distinct favourable subtype in the European Society of Medical Oncology (ESMO) classification. There is broad consensus that these patients are candidates for local ablative treatment strategies with surgery and/or radiotherapy, but data on their outcomes are scarce.In this study, we have addressed the prospects of cure and prognostic factors in a retrospective cohort of 63 patients who were eligible for local treatment at our centre.Median event-free (EFS) and overall survival (OS) were 15.6 months and 52.5 months, respectively. Of 61 patients who received local treatment, 20 (32.8%) remained event-free over a median follow-up of 28 months. Baseline clinical parameters including affected organ, number, volume and histology of metastases had no significant impact on prognosis, whereas deleterious TP53 mutations and DNA copy number loss emerged as independent adverse risk factors with respect to EFS. Surgical treatment was associated with improved OS as compared to radiation-based therapy.Our study advocates to pursue localised treatment with surgery and/or radiotherapy whenever feasible and implies that genetic parameters might additionally determine the clinical course of single-site CUP patients.
000176959 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000176959 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000176959 650_7 $$2Other$$aCUP (cancer of unknown primary)
000176959 650_7 $$2Other$$aCopy number loss
000176959 650_7 $$2Other$$aOligometastasis
000176959 650_7 $$2Other$$aPrognosis
000176959 650_7 $$2Other$$aRadiotherapy
000176959 650_7 $$2Other$$aSingle metastatic deposit
000176959 650_7 $$2Other$$aSurgery
000176959 650_7 $$2Other$$aTP53
000176959 7001_ $$0P:(DE-He78)de9da69e07eba6d0ca82a4f087a64a28$$aWohlfromm, Timothy$$b1$$udkfz
000176959 7001_ $$0P:(DE-He78)a3903480c7232195efbd7b0f6f8564e8$$aKraft, Bianca$$b2$$udkfz
000176959 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b3$$udkfz
000176959 7001_ $$aStichel, Damian$$b4
000176959 7001_ $$avon Deimling, Andreas$$b5
000176959 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, Stefan$$b6$$udkfz
000176959 7001_ $$aEndris, Volker$$b7
000176959 7001_ $$aNeumann, Olaf$$b8
000176959 7001_ $$aStenzinger, Albrecht$$b9
000176959 7001_ $$0P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aKrämer, Alwin$$b10$$udkfz
000176959 7001_ $$0P:(DE-He78)c741dc7f974390ad4310349f29aac40b$$aBochtler, Tilmann$$b11$$eLast author$$udkfz
000176959 773__ $$0PERI:(DE-600)1468190-0$$a10.1016/j.ejca.2021.08.019$$gVol. 157, p. 179 - 189$$p179 - 189$$tEuropean journal of cancer$$v157$$x0959-8049$$y2021
000176959 909CO $$ooai:inrepo02.dkfz.de:176959$$pVDB
000176959 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d62d536fb73eb7644201ddaac56cf68f$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000176959 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)de9da69e07eba6d0ca82a4f087a64a28$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000176959 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a3903480c7232195efbd7b0f6f8564e8$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000176959 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000176959 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000176959 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000176959 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c741dc7f974390ad4310349f29aac40b$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000176959 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000176959 9141_ $$y2021
000176959 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-28$$wger
000176959 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CANCER : 2019$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-28
000176959 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J CANCER : 2019$$d2021-01-28
000176959 9201_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x0
000176959 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000176959 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x2
000176959 980__ $$ajournal
000176959 980__ $$aVDB
000176959 980__ $$aI:(DE-He78)A360-20160331
000176959 980__ $$aI:(DE-He78)C060-20160331
000176959 980__ $$aI:(DE-He78)E010-20160331
000176959 980__ $$aUNRESTRICTED